Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche up in arms as NICE advises NHS not to use Perjeta

This article was originally published in Scrip

Executive Summary

NICE, the health technology assessment institute for England and Wales, is gearing up to advise the NHS that Roche's breast cancer drug Perjeta (pertuzumab) should not be routinely used as it is not value for money. The Swiss pharma company has responded with strong criticism of the Department of Health (DH), which has delayed a review of the company's proposed patient access scheme, accusing it of letting patients down and pointing to flaws in the UK's "creaking system."






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts